171 related articles for article (PubMed ID: 22174876)
1. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells.
Fong V; Osterbur M; Capella C; Kim YE; Hine C; Gorbunova V; Seluanov A; Dewhurst S
PLoS One; 2011; 6(12):e28714. PubMed ID: 22174876
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the human glycoprotein hormone common alpha subunit gene by cAMP-response-element-binding protein (CREB)-binding protein (CBP)/p300 and p53.
Zhang X; Grand RJ; McCabe CJ; Franklyn JA; Gallimore PH; Turnell AS
Biochem J; 2002 Nov; 368(Pt 1):191-201. PubMed ID: 12164786
[TBL] [Abstract][Full Text] [Related]
4. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Watts GS; Oshiro MM; Junk DJ; Wozniak RJ; Watterson S; Domann FE; Futscher BW
Neoplasia; 2004; 6(3):187-94. PubMed ID: 15153330
[TBL] [Abstract][Full Text] [Related]
5. Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector.
Tamura RE; Hunger A; Fernandes DC; Laurindo FR; Costanzi-Strauss E; Strauss BE
Hum Gene Ther; 2017 Aug; 28(8):639-653. PubMed ID: 28181816
[TBL] [Abstract][Full Text] [Related]
6. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.
Tamura RE; da Silva Soares RB; Costanzi-Strauss E; Strauss BE
Cancer Biol Ther; 2016 Dec; 17(12):1221-1230. PubMed ID: 27646031
[TBL] [Abstract][Full Text] [Related]
7. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.
Hannay JA; Liu J; Zhu QS; Bolshakov SV; Li L; Pisters PW; Lazar AJ; Yu D; Pollock RE; Lev D
Mol Cancer Ther; 2007 May; 6(5):1650-60. PubMed ID: 17513613
[TBL] [Abstract][Full Text] [Related]
8. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.
Arias-Lopez C; Lazaro-Trueba I; Kerr P; Lord CJ; Dexter T; Iravani M; Ashworth A; Silva A
EMBO Rep; 2006 Feb; 7(2):219-24. PubMed ID: 16322760
[TBL] [Abstract][Full Text] [Related]
9. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.
Sauthoff H; Pipiya T; Heitner S; Chen S; Norman RG; Rom WN; Hay JG
Hum Gene Ther; 2002 Oct; 13(15):1859-71. PubMed ID: 12396618
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Wang ZX; Bian HB; Yang JS; De W; Ji XH
Cancer Biol Ther; 2009 Aug; 8(15):1480-8. PubMed ID: 19571664
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the promoter region of the human DNA-repair gene Rad51.
Hasselbach L; Haase S; Fischer D; Kolberg HC; Stürzbecher HW
Eur J Gynaecol Oncol; 2005; 26(6):589-98. PubMed ID: 16398215
[TBL] [Abstract][Full Text] [Related]
12. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
13. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
14. CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.
Ogiwara H; Kohno T
PLoS One; 2012; 7(12):e52810. PubMed ID: 23285190
[TBL] [Abstract][Full Text] [Related]
15. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
16. p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells.
Tu SP; Chi AL; Ai W; Takaishi S; Dubeykovskaya Z; Quante M; Fox JG; Wang TC
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G385-96. PubMed ID: 19541923
[TBL] [Abstract][Full Text] [Related]
17. Insulation of a conditionally expressed transgene in an adenoviral vector.
Vassaux G; Hurst HC; Lemoine NR
Gene Ther; 1999 Jun; 6(6):1192-7. PubMed ID: 10455425
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
19. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel recombinant adenovirus containing gfp-zeocin fusion expression cassette for conditional replication in p53-deficient human tumor cells.
Hu B; Joshua MN; Dong C; Qi Y
J Virol Methods; 2004 May; 117(2):129-36. PubMed ID: 15041209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
